

Curriculum Vitae

PAUL ECKBURG, M.D.

Mountain View, CA

peckburg@gmail.com

(650)888-3475

<https://www.linkedin.com/in/paul-eckburg-md-65064/>

SUMMARY

I am an Infectious Diseases & Internal Medicine-trained physician with 25 years of experience in drug development. Over my career in industry R&D, I quickly developed the experience and leadership skills required to serve as Chief Medical Officer (CMO) for 6 companies to date, from early-stage start-ups to a public company, and I'm the president of my own LLC consulting company. Although I've focused on anti-infectives, my experience has spanned many indications (e.g., pulmonary, dermatologic, abdominal, urinary) and non-antibiotic approaches (e.g., phage, microbiota, CRISPR), across acute, chronic, and rare diseases. I have accumulated and continue to build an extensive network of industry professionals and external expert advisors, and I've created and led high-performing Clinical Development (ClinDev) teams and Scientific Advisory Boards. I serve as the medical lead and clinical "face" of companies with regulators (e.g., FDA, EMA, PMDA), advisory boards, conference attendees, industry partners, and funders. My strong work ethic ensures high-quality execution while upholding scientific integrity, in the most efficient and cost-effective manner. I work closely with senior leadership colleagues and Boards of Directors to develop strategies in positively impacting patients' lives, while generating returns for investors. I am absolutely driven to get as many new, transformative medicines approved as possible for patients with high unmet needs for new therapies.

RECENT EXPERIENCE

CMO, AN2 Therapeutics, Inc. (full-time, public company)

Menlo Park, CA 2019–2024

- Advanced drugs for rare, chronic, infectious/pulmonary diseases
- Hired and led the ClinDev team, including Medical Directors & SVP, Biostats, Data Management, ClinMicro, Pharmacovigilance, Clinical Pharm & Medical Affairs
- Heavy involvement in fundraising; on pitch team for an over-subscribed Series B (\$80M) and upsized Nasdaq IPO (\$69M)
- Led clinical strategy in BD, C-suite & Board meetings

President, Eckburg Medical Consulting LLC, see p. 2–3 for detail

US, Europe, India & APAC 2000–present

- **Acting/Interim CMO for 5 Companies**
- Develop clinical strategy and fundraise with C-suites/Boards
- Create ClinDev plans & Phase 1–4 trial designs
- Provide medical monitoring and safety oversight
- Primary writer of clinical sections of regulatory submissions (e.g., INDs, NDAs, CSRs, briefing documents), grants, and protocols

Clinical Assistant Professor, Stanford University

Stanford, CA 2006–present

- Currently Adjunct Faculty position in Infectious Diseases
- Trainee career mentoring and medical school course instructor

STRENGTHS

- **Team Leadership**
— Build, lead, and retain high-functioning ClinDev teams
- **Strategic Vision**
— Develop CDPs with goal of regulatory approvals, with direct understanding of patient journeys, use of new agents, and benefit:risk
- **Outstanding Work Ethic**
— I get in the weeds or effectively delegate to meet all key milestones, and operate as a lifelong learner
- **Humble Collaborator**
— I leave my ego at the door, value teamwork, and constantly improve from mistakes
- **Fast & Flexible**
— Efficiently flex between different company and team styles, always meeting key deadlines
- **Fundraising**
— From VCs to nondilutive funders, including direct Nasdaq IPO experience

SKILLS

- Scientific integrity and patient safety are front-of-mind
- Passionate teacher & mentor
- Experienced oral presenter
- Constant learner in both scientific expertise and leadership training
- Positive mindset and work ethic
- Networking & team-building
- Member of Scientific Advisory Boards
- Chair of Independent DSMB

ACHIEVEMENTS

- Direct involvement in FDA Advisory Committee meetings, NDAs, and FDA approvals (e.g., Teflaro® 2010, Avycaz™ 2015, Nuzyla™ 2018)
- Involvement in 18 Phase 3 trials to date
- Clinical lead on multiple successful nondilutive funding awards, most recently NIAID (AN2) and CARB-X (SNIPR Biome, Geom)
- Invited speaker to multiple international conferences
- First author and presenter of >80 oral abstracts and posters at international meetings, and author of >40 peer-reviewed academic journal manuscripts

Curriculum Vitae

PAUL ECKBURG, M.D.

CURRENT POSITIONS

Eckburg Medical Consulting LLC

■ 2000 – present

Owner and president; ClinDev consultant in drug development

Extensive experience in >30 companies; see “Consulting Experience” below for details.

Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine

■ 2007–present

Adjunct Clinical Assistant Professor in Infectious Diseases

Intermittent role in patient care (Stanford University Hospital) and instructor of the antibiotic lecture series and various medical student classes and workshops (Stanford Medical School).

PRIOR FULL-TIME EMPLOYMENT & EDUCATION

- **AN2 Therapeutics, Inc.**, Menlo Park, CA (Mar 2021–Aug 2024). Full-time CMO. Direct involvement in fundraising, Nasdaq IPO, and business development. Hired and led the ClinDev team, with focus on novel medications for rare, chronic, infectious and pulmonary diseases, e.g., mycobacterial lung infections and global, neglected tropical diseases. Member of BD team, assessing new opportunities in infectious diseases, pulmonology, and oncology. Also consulted for AN2 before and after this FTE; see below.
- **Kalidex Pharmaceuticals, Inc.**, Menlo Park, CA (2011–2012). Senior Director of Medical Affairs. Development of a novel oral fluoroquinolone for multidrug-resistant pathogens.
- **Cerexa, Inc.**, a wholly-owned subsidiary of Forest Laboratories, Oakland, CA (2007–2011). Senior Director of ClinDev. Development of ceftaroline (including 4 Phase 3 studies), among other anti-infectives. Member of BD team, assessing in-licensing opportunities in infectious diseases, among other disease types.
- **Stanford University School of Medicine, Division of Infectious Diseases**, Stanford, CA (2000–2007). Clinical Assistant Professor in Infectious Diseases (2006–2007), Clinical Instructor (2005–2006), and Postdoctoral Research Fellow (2000–2005).
- **Stanford University Medical Center, Department of Internal Medicine**, Stanford, CA (1996–2000). Chief Resident (1999–2000) and Internal Medicine Resident (1996–1999).
- **Rush Medical College**, Chicago, IL (1992–1996). M.D. with Honors.
- **University of Illinois**, Urbana-Champaign, IL (1988–1992). B.S. with Departmental Distinction, Cell and Structural Biology.

CONSULTING EXPERIENCE

- **InClin, Inc.**, San Mateo, CA (Apr 2025–present; 2016–2020). ClinDev review of Phase 1–4 trial CRO bids (multiple indications); Medical Monitoring and safety oversight for Sponsors.
- **Genentech, Inc.**, South San Francisco, CA (Apr 2025–present; Feb 2013–Apr 2016). Advisor for novel anti-infectives targeting multidrug-resistant Gram-negative pathogens.
- **CatalyX Bio, Inc.**, Stanford, CA (Feb 2025–present). Advisor for a Y Combinator software startup focused on AI-facilitated regulatory submissions in biopharma.
- **GangaGen Biotechnologies Pvt Ltd.**, Bangalore, India (Jan 2025–present). Advisor for novel bacteriocins and bacteriophage therapies.
- **NovoBiotic Pharmaceuticals, LLC**, Cambridge, MA (Nov 2024–present). Advisor for a novel antibacterial.
- **AN2 Therapeutics, Inc.**, Menlo Park, CA (Nov 2019–Apr 2021; Sep 2024–Jan 2025). Acting CMO prior to full-time CMO position (see above) and consultant after restructuring in Aug 2025.

Curriculum Vitae
PAUL ECKBURG, M.D.

- **SNIPR Biome**, Copenhagen, Denmark (Aug 2019–May 2021). Interim CMO (Aug 2019–Dec 2020) and Scientific Advisor (2021); ClinDev of novel phage-based CRISPR therapy. Clinical lead on a successful CARB-X award.
- **Bugworks Research, Inc.**, Bangalore, India (May 2019–Nov 2022). Interim CMO (May 2019–Aug 2020), Scientific Advisory Board Member (Sep 2020–Nov 2022); ClinDev of a novel gyrase inhibitor.
- **TenNor Therapeutics**, Shanghai, China (Jul 2018–Apr 2020). Late-stage development of IV TNP-2092, a linked rifamycin and quinolone, for ABSSSI and prosthetic joint infections.
- **Nabriva Therapeutics US, Inc.**, King of Prussia, PA (Jul 2018–Jun 2019). Late-stage development of IV fosfomycin; continuation of Zavante project below.
- **Utility Therapeutics, Ltd.**, Copenhagen, Denmark (Feb 2018–May 2019). Interim CMO; ClinDev of mecillinam/pivmecillinam for U.S. approval.
- **Recida Therapeutics, Inc.**, Menlo Park, CA (Apr 2017–May 2019). Co-founder and Acting VP of ClinDev of a novel LpxC inhibitor.
- **Spero Therapeutics, Inc.**, Cambridge, MA (Jul 2016–Apr 2022). Consultant and Medical Monitor for multiple Phase 1–3 studies in the development of oral tebipenem and novel potentiator polymyxin antibiotics.
- **Achaogen, Inc.**, South San Francisco (Jul 2016–Feb 2017). Phase 4 development of plazomicin and early development of LpxC inhibitor platform.
- **Crestovo, LLC**, Greenwich, CT (Apr 2016–Feb 2018). Phase 2 development of novel full-spectrum microbiota therapy for recurrent *C. difficile* infection.
- **Geom Therapeutics, Inc.**, San Francisco, CA (Apr 2016–May 2019). Acting CMO; development of a novel siderophore antibiotic. Clinical lead on a successful CARB-X award.
- **Zavante Therapeutics, Inc.**, San Diego, CA (Feb 2016–Jul 2018). Acting CMO; U.S. development of IV fosfomycin (Zavante merged with Nabriva in Jul 2018).
- **Wockhardt, Ltd.**, Mumbai, India (Jan 2016–Dec 2016). Phase 3 development of a novel ketolide (nafithromycin) and multiple β -lactam/ β -lactamase inhibitors.
- **Nexgen Biosciences**, San Diego, CA (Sep 2015–Jan 2018). Intermittent, high-level strategy for preclinical development of novel oral β -lactam formulations.
- **Nexcida, Inc.**, Menlo Park, CA (Mar 2015–Apr 2016). Preclinical development of a novel LpxC inhibitor and multiple β -lactamase inhibitors.
- **Cūrza**, Salt Lake City, UT (Feb 2015–present). Scientific Advisory Board member and consultant on a novel antibiotic program.
- **Paratek Pharmaceuticals, Inc.**, King of Prussia, PA (Sep 2014–Aug 2022). Phase 2/3 development of omadacycline for ABSSSI, CABP, and cUTI/AP; DSMB Chair for Phase 3 CABP study (Jan 2021 – Apr 2024).
- **CSR Pharma Group, Inc.**, New Brunswick, NJ (2014). High-level strategy for anti-infective development, with focus on delafloxacin development in China.
- **Cerexa, Inc./Actavis plc**, Oakland, CA (Nov 2013–Dec 2014). Ceftazidime-avibactam Phase 3 HABP/VABP study, NDA submission, and FDA AdCom.
- **MicRx Pharmaceuticals, Inc.**, Hayward, CA (Sep 2013–Apr 2017). IND and Phase 1/2 development of multiple novel oxazolidinones.
- **Aptalis, Inc.**, Bridgewater, NJ (2013–2014). Clinical lead on MAA and NDA submissions for MP-376, an inhaled fluoroquinolone for cystic fibrosis.
- **Rempex Pharmaceuticals, Inc.**, San Diego, CA (2012–2016). Phase 2/3 development of meropenem-vaborbactam (cUTI, HABP/VABP) and oritavancin (bacteremia).

Curriculum Vitae

PAUL ECKBURG, M.D.

- **Hoffmann-La Roche, Inc.**, New York, NY (2012–2013; 2017). High-level strategy and competitive intelligence assessment for early-stage anti-infective development.
- **Cerexa, Inc.**, Alameda, CA (2006–2007). Phase 3 ABSSSI development for ceftaroline prior to full-time employment at Cerexa.
- **Protez Pharmaceuticals, Inc.**, Malvern, PA (2005–2006). Phase 1 protocol development for a novel carbapenem antibiotic (PZ601).
- **Asclepion Consulting, LLC**, Mountain View, CA (2003–2007). Co-founder and Medical Director. Provided scientific opinion for law firms and ClinDev consulting for biotech companies.
- **Peninsula Pharmaceuticals, Inc.**, Fremont CA (2002–2003). Phase 3 cUTI and cIAI development of doripenem.
- **Versicor, Inc.** (later Vicuron), Fremont CA (2000–2001). Pre-Phase 3 development of anidulafungin.

MEDICAL LICENSURE

Physician and Surgeon, State of California (active), certificate number A63142
Original issuance August 1997, Medical Board of California

ACADEMIC RESEARCH EXPERIENCE

- **Stanford University School of Medicine**, Division of Infectious Diseases, Stanford, CA (2001–2007). Research Associate and Postdoctoral Fellowship in Infectious Diseases. Characterization of the human microbiota and its role in health and inflammatory bowel disease.
Advisor: Dr. David A. Relman, Divisions of Microbiology & Immunology and Infectious Diseases, Stanford University School of Medicine.
Publications: See “Peer-reviewed Publications” below.
- **National Institute of Mental Health, NIH**, Bethesda, MD (1993). Summer Research Fellow. Investigated morphological changes in the basal ganglia of children with Sydenham’s chorea, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder, using MRI technology.
Advisor: Dr. Judith L. Rapoport, NIMH, Bethesda MD.
Publication: Castellanos FX, Giedd JN, Eckburg PB, Marsh WL, Vaituzis AC, Kaysen D, Hamburger SD, Rapoport JL. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. *Am J Psychiatry* 1994;151:1791-6.
- **Beckman Institute**, University of Illinois, Urbana-Champaign, IL (1990–1992). Research Assistant. Investigated synaptic plasticity in the rat cerebellar and motor cortices after motor skill learning.
Advisor: Dr. William T. Greenough, Departments of Cell and Structural Biology, Psychology, and Neuroscience, UIUC, Urbana IL
Publication: Anderson BJ, Eckburg PB, Relucio KI. Alterations in the thickness of motor cortical subregions after motor-skill learning and exercise. *Learn Mem* 2002;9:1-9.

ACADEMIC TEACHING EXPERIENCE

- **Stanford University School of Medicine**. Human Health & Disease, Inde221: Annual 6-lecture series on *Antibacterial & Antifungal Agents* (2012–2020). Directors: Donald Regula, Sharon Chen, Manuel Amieva.
- **Stanford University School of Medicine**. Human Health & Disease, Course Inde220: Annual lectures on *Bacterial Pneumonia and Upper Respiratory Tract Infections* (2009–2015). Course director: Robert Siegel.
- **Stanford University School of Medicine**. Human Health & Disease, Courses Inde222 & 223: *Clinical-Pathological Conferences in Infectious Diseases* (2005–present). Course director: Robert Siegel.

Curriculum Vitae

PAUL ECKBURG, M.D.

- **Stanford University School of Medicine.** Stanford Premedical Association, Mentoring Program (2006–2008).
- **Stanford University School of Medicine.** Human Microbial Ecosystems, Biological Sciences 220: *Ecology of Microorganisms* (2005). Director: Brendan Bohannon.
- **Stanford University School of Medicine.** Pharmacology 202: *Antibiotics* (2003).
- **Stanford University School of Medicine.** Infectious Basis of Disease, Microbiology & Immunology 785 (2001–2004). Course director: Robert Siegel.
- **Stanford University School of Medicine.** Infectious Diseases Fellowship (2001–2007). Annual lectures included *Community-acquired Pneumonia, Skin & Soft Tissue Infection, Influenza*.
- **Stanford University School of Medicine.** Internal Medicine Residency Program, (2000–2007).
- **Stanford University School of Medicine.** Preparation for Clinical Medicine (2000).
- **Rush Medical College.** Teaching Assistant for *Human Anatomy* and *Neuroanatomy* courses (1992–1996).

PEER-REVIEWED PUBLICATIONS*

1. Sewunet T, Razavi M, Rosenberg S, Camporeale A, Nowak M, Melnick D, Gasink LB, Eckburg PB, Critchley IA, Nord CE, Giske CG. Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial. *Lancet Microbe* 2024;5:e355-e365.
2. Melnick D, Talley AK, Gupta VK, Critchley IA, Eckburg PB, Hamed KA, Bhatt N, Moore G, Austin D, Rubino CM, Bhavnani SM, Ambrose PG. Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections. *Antimicrob Agents Chemother* 2023;18:67:e0053523.
3. Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan A, Moore G, Jain A, Keutzer T, Dane A, Melnick D, Talley AK. Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. *N Engl J Med* 2022;386:1327-1338.
4. Ramirez J, Deck DH, Eckburg PB, Curran M, Das AF, Kirsch C, Manley A, Tzanis E, McGovern PC. Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: Results from the OPTIC study. *Open Forum Infect Dis* 2021;8:ofab135.
5. Sakoulas G, Eckburg PB, Amodio-Groton M, Manley A, Tzanis E, Das AF, Noble R, McGovern PC. Clinical efficacy of patients with secondary bacteremia treated with omadacycline: Results from Phase 3 acute bacterial skin and skin structure infections and community-acquired pneumonia studies. *Open Forum Infect Dis* 2021; 8(6):ofab136.
6. Gupta VK, Maier G, Eckburg P, Morelli L, Lei Y, Jain A, Manyak E, Melnick D. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of tebipenem pivoxil hydrobromide on QT/QTc intervals in healthy subjects. *Antimicrob Agents Chemother* 2021;65:e0014521.
7. Torres A, Garrity-Ryan L, Kirsch C, Steenbergen JN, Eckburg PB, Das AF, Curran M, Manley A, Tzanis E, McGovern PC. Omadacycline versus moxifloxacin in adults with community-acquired bacterial pneumonia. *Int J Infect Dis* 2021;104:501-509.
8. O’Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E, on behalf of the OASIS-2 Investigators. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. *Lancet Infect Dis* 2019;19:1080-1090.
9. Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen J, Das AF, Eckburg PB, McGovern PC. Omadacycline for acute bacterial skin and skin structure infections. *Clin Infect Dis* 2019;69(Suppl 1):S23-S32.
10. Eckburg PB, Jain A, Walpole S, Moore G, Utley L, Manyak E, Dane A, Melnick D. Safety, pharmacokinetics, and food effect of tebipenem pivoxil hydrobromide after single and multiple ascending oral doses in healthy adult subjects. *Antimicrob Agents Chemother* 2019;63:e00618-19.
11. Eckburg PB, Lister T, Walpole S, Keutzer T, Utley L, Tomayko J, Kopp E, Farinola N, Coleman S. Safety, tolerability, pharmacokinetics, and drug interaction potential of SPR741, an intravenous potentiator, after single and multiple ascending doses and when combined with β -lactam antibiotics in healthy subjects. *Antimicrob Agents Chemother* 2019;63:e00892-19.
12. Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, Das A, Skarinsky D, Eckburg PB, Ellis-Grosse EJ. Fosfomycin for injection (ZTI-01) vs piperacillin-tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2/3 randomized trial. *Clin Infect Dis* 2019;69:2045-2056.
13. O’Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Ph.D., Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. Omadacycline for acute bacterial skin and skin-structure infections. *N Engl J Med* 2019;380:528-38.
14. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. *N Engl J Med* 2019;380:517-27.
15. Eckburg PB, Ge Y, Hafkin B. Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects. *Antimicrob Agents Chemother* 2017;61:e02181-16.
16. File TM, Eckburg PB, Talbot GH, Llorens L, Friedland HD. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcomes assessment at an early time point. *Int J Antimicrob Agents* 2017;50:247-251.

Curriculum Vitae

PAUL ECKBURG, M.D.

17. Jandourek A, Smith A, Llorens L, Thye D, Eckburg PB, Friedland HD. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia: Pooled analysis from 2 randomized clinical trials. *Hosp Practice* 2014;42:75-78.
18. Shorr A, Kollef M, Eckburg PB, Llorens L, Xie L, Friedland HD. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to *Streptococcus pneumoniae*: insights from two randomized trials. *Diagn Microbiol Infect Dis* 2013;75:298-303.
19. Eckburg PB, Friedland HD, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D. Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for CABP. *Infect Dis Clin Practice* 2012;20:254-260.
20. Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D. CANVAS 1 and 2: Analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. *Antimicrob Agents Chemother* 2012;56(5):2231-2236.
21. File T, Low D, Eckburg PB, Talbot G, Friedland HD, Lee J, Llorens L, Critchley IA, Thye D. FOCUS 1: A Randomised, double-blinded, multicentre, phase 3 trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. *J Antimicrob Chemother* 2011;66 (Suppl 3):iii19–iii32.
22. Low D, File T, Eckburg PB, Talbot G, Friedland HD, Lee J, Llorens L, Critchley IA, Thye D. FOCUS 2: A Randomised, double-blinded, multicentre, phase 3 trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. *J Antimicrob Chemother* 2011;66 (Suppl 3):iii33–iii44.
23. Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye D. FOCUS 2: A Review of ceftaroline fosamil microbiology: integrated FOCUS studies. *J Antimicrob Chemother* 2011;66 (Suppl 3):iii45–iii51.
24. File T, Low D, Eckburg PB, Talbot G, Friedland D, Lee J, Llorens L, Critchley IA, Thye D. Integrated analysis of FOCUS 1 and 2: Randomized, double-blinded multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. *Clin Infect Dis* 2010;51:1395-1405.
25. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. *Clin Infect Dis* 2007;44:256-62.
26. Chiu CY, Rouskin S, Koshy A, Urisman A, Fischer K, Yagi S, Schnurr D, Eckburg PB, Tompkins LS, Blackburn BG, Merker JD, Patterson BK, Ganem D, DeRisi JL. Microarray diagnosis of human parainfluenza 4 infection associated with respiratory failure in an immunocompetent adult. *Clin Infect Dis* 2006;43:e71-6.
27. Dethlefsen L, Eckburg PB*, Bik EM*, Relman DA. Assembly of the human intestinal microbiota. *Trends Ecol Evol* 2006;21:517-23 (*contributed equally).
28. Gill SR, Pop M, DeBoy RT, Eckburg PB, Hanace I, Relman DA, Nelson KE. Metagenomic analysis of the human gastrointestinal microbiome. *Science* 2006;312:1355-59.
29. Palmer C, Bik EM, Eisen MB, Eckburg PB, Sana T, Wolber P, Relman DA, Brown PO. Rapid quantitative profiling of complex microbial populations. *Nucleic Acids Res* 2006;34(e5):1-10.
30. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom E, Francois F, Perez-Perez GI, Blaser MJ, Relman DA. Molecular analysis of the bacterial flora of the human stomach. *Proc Nat Acad Sci USA* 2006;103:732-737.
31. Eckburg PB, Schneider JJ, Renault CA. Avian influenza in humans: a practical review for clinicians. *Infect Med* 2005;22:535-542.
32. Renault CA, Eckburg PB. An uncommon cause of malignant otitis externa. *Infect Med* 2005;22:566.
33. Eckburg PB, Bik EM, Bernstein CB, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. *Science* 2005;308:1635-1638.
34. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. *Lancet Infectious Diseases* 2004;4:15-25.
35. Eckburg PB, Lepp PW, Relman DA. Archaea and their potential role in human disease. *Infection and Immunity* 2003;71:591-596.
36. Eckburg PB, Montoya JG, Vosti KL. Brain abscess due to *Listeria monocytogenes*: 5 cases and review of the literature. *Medicine* 2001;80:223-235.
37. Eckburg PB, Buadu EO, Stark P, Sarinas PS, Chitkara RK, Kuschner WG. Clinical and chest radiographic findings among persons with sputum culture positive for *Mycobacterium gordonae*: a review of 19 cases. *Chest* 2000;117:96-102.
38. Eckburg PB, Zolopa AR, Montoya JG. Invasive fungal sinusitis due to *Scedosporium apiospermum* in a patient with AIDS. *Clin Infect Dis* 1999;29:212-3.

*Additional citations include >80 oral presentations, poster presentations, and book chapters; citations available by request.